← Back to Search

Vasopressor Agent

Angiotensin II for Septic Shock

Phase 4

Waitlist Available

Led By Alexander H Flannery, Pharm.D.

Research Sponsored by Alexander Flannery

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 months following enrollment

Awards & highlights

Study Summary

This trial is testing if angiotensin II, a new FDA approved vasopressor agent, could help improve survival rates of septic shock patients, specifically those requiring continuous renal replacement therapy, those with altered angiotensin I: angiotensin II ratios, and those with elevated renin levels.

Eligible Conditions

Septic Shock
Acute Kidney Injury

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 months following enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 months following enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 months following enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Plasma Renin Levels

Secondary outcome measures

Change in Renal Biomarkers

ICU Length of Stay

In-hospital mortality

+3 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Angiotensin II CohortExperimental Treatment1 Intervention

Patients in this group will receive angiotensin II.

Group II: Standard of Care CohortActive Control1 Intervention

Patients in this group will receive standard of care treatment.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Angiotensin II

2010

Completed Phase 4

~260

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Alexander FlanneryLead Sponsor

1 Previous Clinical Trials

56 Total Patients Enrolled

Alexander H Flannery, Pharm.D.Principal InvestigatorUniversity of Kentucky

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the Food and Drug Administration greenlighted Angiotensin II as a safe pharmaceutical?

"The safety of Angiotensin II has been confirmed with clinical evidence, making it eligible for a score of 3."

Answered by AI

Are there any spots left open to take part in this experiment?

"Affirmative. The clinical trial is open for recruitment, as indicated on clinicaltrials.gov; it was originally posted on October 19th 2020 and the last update occurred on December 1st 2021. A total of 30 patients are needed to be enrolled at one site."

Answered by AI

To what extent are participants being observed in this research?

"Indeed, clinicaltrials.gov has revealed that this trial is actively seeking applicants since its inception on October 19th 2020 and the most recent change to it was made December 1st 2021. The study seeks out 30 individuals from a single medical site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Renin and Renal Biomarker Response to Angiotensin II

Alexander Flannery 2020. "Renin and Renal Biomarker Response to Angiotensin II". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04558359.